WuXi AppTec Wins SCRIP Award for "Best Company in an Emerging Market"
Dec 04, 2014
SHANGHAI, Dec. 4, 2014 -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, with operations in China and the United States, announced today that it has won the SCRIP Award in the category of "Best Company in an Emerging Market." This award recognizes the rapid growth, significant accomplishments, and increasing global presence achieved by WuXi AppTec in 2014. This is the first time a China-based company has won this SCRIP Award. WuXi AppTec was presented with the award at the 10th Annual SCRIP Awards ceremony held in London on December 3, 2014.
Established in 2005 by SCRIP Intelligence, a leading industry news and strategic analysis firm covering the global pharmaceutical and biotech sectors, the annual SCRIP Awards acknowledge the most significant achievements of outstanding companies worldwide.
"We are greatly honored to receive this prestigious industry award and to play a role in helping our partners develop innovative products through our open-access capability and technology platform," said Dr. Ge Li, Chairman and CEO of WuXi AppTec. "This award belongs to our employees and collaborative partners around the globe, whose efforts, ingenuity and dedication are making a real difference in the quest to discover and develop new medicines for patients."
About WuXi PharmaTech
WuXi PharmaTech (NYSE: WX) is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.
For more information, please contact:
Director of Investor Relations
+1 (201) 585-2048
Director of Corporate Communications